<SEC-DOCUMENT>0001213900-22-082294.txt : 20221223
<SEC-HEADER>0001213900-22-082294.hdr.sgml : 20221223
<ACCEPTANCE-DATETIME>20221222193122
ACCESSION NUMBER:		0001213900-22-082294
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20221223
FILED AS OF DATE:		20221223
DATE AS OF CHANGE:		20221222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		221483163

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea170794-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the Month of December 2022</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Name of Registrant)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton South, Victoria,
3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Yes &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Immuron Limited (the &ldquo;Company&rdquo;) published
one announcement (the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange on December 23, 2022 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Immuron
Receives FDA Approval for Travelan IND Application&rdquo;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 273pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A copy of the Public Notice is attached as an exhibit to this report on
Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This report on Form 6-K (including the exhibit hereto)
shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)
and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly
set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B> <BR>
<B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea170794ex99-1_immuron.htm">IMC - Immuron Receives FDA Approval for Travelan IND Application</A> </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><IMG SRC="image_001.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 23, 2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea170794ex99-1_immuron.htm
<DESCRIPTION>IMC - IMMURON RECEIVES FDA APPROVAL FOR TRAVELAN IND APPLICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immuron Receives FDA Approval for Travelan IND
Application </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Highlights:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Immuron
receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application</B></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IND
to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by ETEC is now active</B></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Plans
in place to initiate a Human clinical trial in 60 healthy volunteers in the USA</B></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Clinical
Trial to examine a dosing regimen for Travelan more suited for use by the US military</B></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Infectious
diarrhea is the most common illness reported by travelers</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Melbourne, Australia, December 23, 2022: Immuron
Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially
available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that it has received approval
from the US Food and Drug Administration to proceed with the clinical evaluation of Travelan. The Investigational New Drug (IND) application
to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by ETEC is now active.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">As
a </FONT>result of this approval the company will proceed with the planned clinical trial in the United States. The safety and protective
efficacy of Travelan will be tested utilizing a controlled human infection-model clinical trial design.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Immuron is the sponsor
of the IND, and the clinical study will be conducted by the Contract Research Organisation Pharmaron CPC, Inc (ASX announcement October
4, 2022) at its FDA inspected clinical research facility located in Baltimore, Maryland in the USA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Phase II clinical
trial will evaluate the efficacy of a single dose regimen of Travelan&reg; in a controlled human infection model (CHIM) using the enterotoxigenic
<I>Escherichia coli</I> (ETEC) strain H10407. The clinical study aims to enrol up to 60 healthy adult subjects each will be randomly assigned
to receive either a once-daily dose of 1200 mg of Travelan&reg; (30 subjects) or placebo (30 subjects). Recruitment is planned to be initiated
in 1H 2023 with headline results from the clinical trial expected to be reported by year end 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Infectious diarrhea is the most common illness
reported by travelers visiting developing countries and among US troops deployed overseas. The morbidity and associated discomfort stemming
from diarrhea decreases daily performance, affects judgment, decreases morale and declines operational readiness. The first line of treatment
for infectious diarrhea is the prescription of antibiotics. Unfortunately, in the last decade, several enteric pathogens have an increasing
resistance to commonly prescribed antibiotics. In addition, travelers&rsquo; diarrhea is now recognized by the medical community to result in
post-infectious sequelae, including post-infectious Irritable Bowel Syndrome and several post-infectious autoimmune diseases. A preventative
treatment that protects against enteric diseases, is a high priority objective for the US Military.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release has been authorised by the directors
of Immuron Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - END - - -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COMPANY CONTACT:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Steven Lydeamore</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ph: +61 (0)3 9824 5254</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">info@immuron.com</P></TD>
    <TD STYLE="width: 40%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><B><IMG SRC="ex99-1_002.jpg" ALT="" STYLE="height: 69px; width: 670px">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About Travelan&reg;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Travelan&reg; is an
orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea, <FONT STYLE="background-color: white">a
digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce</FONT>. Travelan&reg; is a highly
purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing
bacteria and prevent colonization and the pathology associated with travelers&rsquo; diarrhea. In Australia, Travelan&reg; is a listed
medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea,
reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan&reg; is a licensed natural health product
(NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea. In the U.S., Travelan&reg; is sold as a dietary supplement
for digestive tract protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About Travelers&rsquo; diarrhea</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Travelers&rsquo; diarrhea
is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating,
and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic <I>Escherichia coli</I> (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella
spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused
with travelers&rsquo; diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>About Immuron</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of inflammatory mediated and infectious diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">For more information
visit: http://www.immuron.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FORWARD-LOOKING STATEMENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management&rsquo;s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_002.jpg" ALT="" STYLE="height: 69px; width: 670px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ #H# 2(  A$! Q$!_\0
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MJM%<(UY-;EAYB -C_9/3]<U9/3BL+5[AM-U+3[TJ/(>3[+._=0WW#_WUQ^-
M&]134/6G4 %%%% !1110 50U73X=4TNXL)]PCGC*%EZKZ$>X."/I5^FN-PQQ
M^- &)X9U*:]TPPWF!?V;FVNE_P!M?XOHRX8?6M:6XBB*>9(J;V"+N.,L>P]Z
MY?6C_P (]XFM==7Y;*\VV>H<\*<_NI3]"=I/HPJ3Q1=*NI^&K4C+7&J*0/\
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GVTA"C. &.3^M '5BB@44 %%%% !1110 4F!Z444  X7BEHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 0P# 2(  A$! Q$!_\0
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MH/Q7F\]8=;@0QL<>?",%?JO?\*V?$_Q+LM*(M]+5+VX*@F3=^[3(XZ=36?\
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MI[9:3FXL8+@@ R1JY [9&:\[T[XG32^(197\%M!:!W#S9.5"@G^@KO\ 2_\
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M*OOJG_H0KC/A!_R%M2_ZX+_Z%7:?$/\ Y$F^_P" ?^A"N+^$'_(4U+_K@O\
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M4H-6TNWOK=@T<R!N.Q[CZ@TL8KTZ<EM;_(,([5*D7O?_ #+E>&?$S_D=Y_\
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98Y&&&D8EG/XFM:BBLY2<G=LTC%15DC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 S$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;\1>'M"\--]J739#<23HIVQ1JC+C<>I8L*T(;LQ3>,M,B/[F"-IHP.B%XR6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1T4#'%W/5F/XTVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /J*BO%?^%J^(?[EE_P!^C_\ %4X?
M%?7QUAL3_P!LF_\ BJ^9_LO$>7WGUG]KX;S^X]HHKQD?%C7O^?>Q_P"_;?\
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M^3^]^E1T4 /\Z3^\:3S'_OG\Z;10 NYC_$?SI,GU-%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
